Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for a coronary or peripheral diagnostic or interventional procedure~* Able to undergo emergent vascular surgery if a complication requires it~* 6F arterial puncture located in the common femoral artery~* Femoral artery has a lumen diameter of at least 5 mm~Exclusion Criteria:~* Arterial puncture in the femoral artery of both legs~* Prior target artery closure with any vascular closure device, or closure with manual compression within 30 days prior to catheterization~* Patients who bruise or bleed easily or with a history of significant bleeding or platelet disorders~* Acute ST-elevation myocardial infarction within 48 hours prior to catheterization~* Uncontrolled hypertension at time of vessel closure~* Elevated Activated Clotting Time at time of vessel closure~* Ineligible for in-catheterization lab introducer sheath removal~* Concurrent participation in another investigational device or drug trial~* Thrombolytic therapy, bivalirudin, other thrombin-specific anticoagulants, or low molecular weight heparin within 24 hours prior to catheterization~* Preexisting hematoma, arteriovenous fistula, or pseudoaneurysm at the vessel access site prior to femoral artery closure~* Prior femoral vascular surgery or vascular graft in region of access site~* Femoral artery is tortuous or requires an introducer sheath longer than 11 cm~* Fluoroscopically visible calcium, atherosclerotic disease, or stent within 1 cm of the puncture site that would interfere with the operation of the experimental device~* Difficulty in obtaining vascular access resulting in multiple arterial punctures and/or posterior arterial puncture~* Antegrade vascular puncture~* Body Mass Index over 40 kg/m\^2~* Symptomatic leg ischemia in the target limb including severe claudication or weak/absent pulse~* Femoral artery diameter stenosis exceeding 50%~* Pre-existing severe non-cardiac systemic disease or terminal illness~* Planned arterial access at the same access site within 30 days of catheterization~* Extended hospitalization (e.g. Coronary Artery Bypass Graft (CABG) surgery)~* Pre-existing systemic or cutaneous infection~* Prior use of an intra-aortic balloon pump through the arterial access site~* Cardiogenic shock during or immediately following the catheterization~* Patient is unable to ambulate at baseline~* Patient is known or suspected to be pregnant or is lactating~* Patient is unavailable for follow-up~* Any angiographic or clinical evidence that the physician feels would place the patient at increased risk with the use of the experimental device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Manual Compression (Type: ACTIVE_COMPARATOR): Manual compression (MC)
- Vascular Closure Device (Type: EXPERIMENTAL): Vascular Closure Device (VCD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete